share_log

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Lisata Therapeutics 將參加即將於 2024 年 4 月舉行的行業和投資者活動
Lisata Therapeutics ·  04/03 12:00

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April:

新澤西州巴斯金裏奇,2024年4月3日(環球新聞專線)——開發治療晚期實體瘤和其他嚴重疾病創新療法的臨床階段製藥公司Lisata Therapeutics, Inc.(納斯達克股票代碼:LISATA)(“Lisata” 或 “公司”)今天宣佈,Lisata總裁兼首席執行官戴維·馬佐博士將在4月參加以下活動:

LD Micro Invitational XIV (April 8-9, 2024)
Format: In-person and On-demand
Location: Sofitel New York Hotel in New York City
Presentation Date: Tuesday, April 9, 2024
Presentation Time: 10:00 a.m. Eastern Time
Presentation Track: Track 4 – Montmartre

LD 微型邀請賽 XIV(2024 年 4 月 8 日至 9 日)
格式:面對面和點播
地點:紐約市的索菲特紐約酒店
演講日期:2024 年 4 月 9 日星期二
演講時間:美國東部時間上午 10:00
演示曲目:曲目 4 — 蒙馬特

Register for Webcast: https://ldinv14.sequireevents.com/

註冊觀看網絡直播: https://ldinv14.sequireevents.com/

Management will be available for one-on-one meetings with registered investors of the conference. Please reach out to the Lisata representative under the contact section below or Dean Summers at LD Micro (dean@ldmicro.com) to register for the event and schedule a meeting with the Company.

管理層將可以與會議的註冊投資者進行一對一的會面。請通過以下聯繫部分聯繫Lisata代表或LD Micro的迪恩·薩默斯(dean@ldmicro.com) 註冊參加活動並安排與公司的會議。

FORCE Family Office Webinar with Lisata Therapeutics (April 10, 2024)
Format: Webinar - Virtual
Webinar Date: Wednesday, April 10, 2024
Webinar Time: 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time

與Lisata Therapeutics合作的FORCE家族辦公室網絡研討會(2024年4月10日)
形式:網絡研討會-虛擬
網絡研討會日期:2024 年 4 月 10 日星期三
網絡研討會時間:東部時間下午 12:00 /太平洋時間上午 9:00

Webinar details will be provided upon RSVP approval. To register for the event, please visit www.forcefamilyoffice.com/events/healthcare/lisata-therapeutics-coming-april-10-2024

網絡研討會的詳細信息將在RSVP批准後提供。要註冊參加此次活動,請訪問 www.forcefamilyoffice.com/events/healthcare/lisata-therapeics-coming-2024 年 4 月

Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (April 17-18, 2024)
Format: Virtual
Presentation Date: Wednesday, April 17, 2024
Presentation Time: 1:30 p.m. Eastern Time

諾布爾資本市場新興增長虛擬醫療股票會議(2024年4月17日至18日)
格式:虛擬
演講日期:2024 年 4 月 17 日,星期三
演講時間:美國東部時間下午 1:30

Management will be available for one-on-one meetings with registered investors of the conference. Please reach out to the Lisata representative under the contact section below or events@noblecapitalmarkets.com to register for the event and schedule a meeting with the Company. For more information on the event, please visit https://bit.ly/3VwVxbz.

管理層將可以與會議的註冊投資者進行一對一的會面。請在下面的聯繫部分下與 Lisata 代表聯繫,或 events@noblecapitalmarkets.com 註冊參加活動並安排與公司的會面。有關該活動的更多信息,請訪問 https://bit.ly/3VwVxbz

Immuno-Oncology Summit Europe (April 23-25, 2024)
Format: In-person and On-demand
Location: Hilton London Canary Wharf in London, UK
Presentation Date: Tuesday, April 23, 2024
Presentation Time: 4:30 p.m. British Summer Time / 11:30 a.m. Eastern Time
Conference Program: Modulating the Tumour Microenvironment

歐洲免疫腫瘤學峯會(2024 年 4 月 23-25 日)
格式:面對面和點播
地點:英國倫敦金絲雀碼頭希爾頓酒店
演講日期:2024 年 4 月 23 日,星期二
演講時間:英國夏令時間下午 4:30 /東部時間上午 11:30
會議日程:調節腫瘤微環境

To register for the event, please visit www.immuno-oncologyeurope.com.

要註冊參加此次活動,請訪問 www.immuno-oncologyeurope.com

About Lisata Therapeutics

關於 Lisata Therapeu

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata's CendR Platform Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.

Lisata Therapeutics 是 處於臨床階段的製藥公司 致力於發現、開發和商業化治療晚期實體瘤和其他主要疾病的創新療法。Lisata的主要候選產品, LSTA1,是一種在研藥物,旨在激活一種新的攝取途徑,使共同使用或聯用的抗癌藥物能夠更有效地靶向和穿透實體瘤。基於 Lisata 的 cENDR 平台 科技,Lisata已經建立了值得注意的商業和研發合作伙伴關係。該公司預計將在未來兩年內宣佈許多臨床研究和業務里程碑,並預計其當前的業務和發展計劃將通過這些里程碑到2026年初的可用資本提供資金。有關該公司的更多信息,請訪問 www.lisata.com

Contact:

聯繫人:

Investors and Media:

投資者和媒體:

Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

Lisata Therapeutics, In
約翰·門迪託
投資者關係和企業傳播副總裁
電話:908-842-0084
電子郵件: jmenditto@lisata.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論